Ginkgo files updated pro forma financials for Zymergen acquisition; pro forma net loss $2.4B

Ginkgo Bioworks Holdings, Inc.

Pro forma combined revenue $487.8M for FY 2022; Ginkgo standalone $477.7M, Zymergen $10.1M.
Pro forma net loss attributable to Ginkgo stockholders $2.405B; diluted EPS loss $1.37.
Adjustments include $8.1M net reduction in operating expenses from fair value and compensation changes.
Weighted average shares outstanding increased to 1.76B from 1.68B due to Merger consideration shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.